TickerFacts.

Mineralys Therapeutics, Inc. (MLYS): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$142.43M
Year ended 2025-12-31
2023-12-31: -$81.17M2024-12-31: -$166.41M2025-12-31: -$142.43M-$142.43M
2023-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$142.43Mn/m2026-03-12, From 2025-01-01
2024-12-31-$166.41Mn/m2026-03-12, From 2024-01-01
2023-12-31-$81.17Mn/a2025-02-12, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Mineralys Therapeutics, Inc. (MLYS)2025-12-31-$142.43Mn/m
Protagonist Therapeutics, Inc (PTGX)2025-12-31$56.08M-69.3%
Immunome Inc. (IMNM)2025-12-31-$200.60Mn/m
Wave Life Sciences, Inc. (WVE)2025-12-31-$188.21Mn/m
Nurix Therapeutics, Inc. (NRIX)2025-11-30-$263.47Mn/m
Axsome Therapeutics, Inc. (AXSM)2025-12-31-$93.89Mn/m
Xenon Pharmaceuticals Inc. (XENE)2025-12-31-$279.92Mn/m
Bicycle Therapeutics PLC (BCYC)2025-12-31-$252.03Mn/m
Arvinas, Inc. (ARVN)2025-12-31-$275.70Mn/m

Compare MLYS, PTGX, IMNM, WVE side by side · Screen every company in Pharmaceutical Preparations ↗